


Halozyme Therapeutics

Biotech company from the U.S.


- Platform technology for converting intravenous drugs into subcutaneous applications
- Halozyme has licensed its ENHANZE technology to leading pharmaceutical and biotechnology companies including Roche, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and Argenx
- Successful transition to a profitable, high-growth company
- Estimated 5 new products will reach clinical phases in 2021
- Favored market trend with increased use of antibodies



Long process



Uses proprietary, Halozyme rHuPH20 enzyme



Facilitates the dispersion and absorption of other drugs

ESG Risk Rating

26.8

- Negligible
- Low
- **Medium**
- High
- Severe

UN Global Compact

- **Compliant**
- Watchlist
- Non-compliant

Controversy scale

0

- Low
- Moderate
- **Significant**
- High
- Severe

Controversial business areas

- **Animal testing***
- *Pharmaceutical products, medical devices and biotechnology (no cosmetics)